

September 9, 2020



Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Live video webcast with CEO, Jeffrey Eisenberg, on Wednesday, September 16th at 12:00 PM EDT

FRAMINGHAM, MA / ACCESSWIRE / September 9, 2020 / [Xenetic Biosciences, Inc.](#) (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that [Jeffrey Eisenberg, Chief Executive Officer](#) of Xenetic will present at [H.C. Wainwright 22nd Annual Global Investment Conference](#) on Wednesday, September 16, 2020 at 12:00 PM EDT.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website [here](#).

A live [video webcast](#) of the presentation will be available on the [IR Calendar](#) page of the [Investors](#) section of the Company's website ([xeneticbio.com](#)). The video webcast replay will be made available two hours following the event and will be archived for 90 days.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

For more information, please visit the Company's website at [www.xeneticbio.com](#) and connect on [Twitter](#), [LinkedIn](#), and [Facebook](#).

CONTACT:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/604851/Xenetic-Biosciences-Inc-to-Present-at-the-HC-Wainwright-22nd-Annual-Global-Investment-Conference>